Strategic Wealth Advisors Group LLC Takes $85,000 Position in Calithera Biosciences, Inc. (NASDAQ:CALA)

Strategic Wealth Advisors Group LLC acquired a new stake in Calithera Biosciences, Inc. (NASDAQ:CALA) in the second quarter, Holdings Channel.com reports. The firm acquired 40,600 shares of the biotechnology company’s stock, valued at approximately $85,000.

Several other institutional investors and hedge funds have also recently modified their holdings of CALA. BVF Inc. IL increased its position in shares of Calithera Biosciences by 27.6% during the first quarter. BVF Inc. IL now owns 5,566,690 shares of the biotechnology company’s stock worth $13,471,000 after purchasing an additional 1,205,452 shares in the last quarter. Altium Capital Management LP purchased a new stake in shares of Calithera Biosciences during the first quarter worth approximately $2,066,000. BlackRock Inc. increased its position in shares of Calithera Biosciences by 14.2% during the first quarter. BlackRock Inc. now owns 6,474,723 shares of the biotechnology company’s stock worth $15,670,000 after purchasing an additional 806,323 shares in the last quarter. Axiom Investment Management LLC purchased a new stake in shares of Calithera Biosciences during the first quarter worth approximately $614,000. Finally, Renaissance Technologies LLC increased its position in shares of Calithera Biosciences by 75.3% during the first quarter. Renaissance Technologies LLC now owns 560,855 shares of the biotechnology company’s stock worth $1,357,000 after purchasing an additional 240,955 shares in the last quarter. Hedge funds and other institutional investors own 63.29% of the company’s stock.

NASDAQ CALA opened at $2.05 on Wednesday. The stock’s fifty day moving average is $2.15 and its two-hundred day moving average is $2.27. The firm has a market capitalization of $151.93 million, a P/E ratio of -1.85 and a beta of 1.69. Calithera Biosciences, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $6.18.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.05. The company had revenue of $3.00 million for the quarter. On average, equities research analysts predict that Calithera Biosciences, Inc. will post -0.83 earnings per share for the current fiscal year.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Calithera Biosciences in a research note on Monday, August 9th.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor.

Further Reading: When can a hold rating present a buying opportunity?

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences, Inc. (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.